ETHE1 Human

Ethylmalonic Encephalopathy 1 Human Recombinant
Cat. No.
BT7670
Source
E.coli.
Synonyms
Ethylmalonic encephalopathy protein 1, HSCO, Hepatoma subtracted clone one protein, YF13H12, protein ETHE1 mitochondrial, D83198, EC 3.1.2.6.
Appearance
Sterile Filtered colorless solution.
Purity
Greater than 90% as determined by SDS-PAGE.
Usage
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs
In Stock

Description

ETHE1 Human Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 267 amino acids (13-254) and having a molecular mass of 29.1kDa.
ETHE1 is fused to a 25 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.

Product Specs

Introduction
ETHE1, a mitochondrial sulfur dioxygenase, plays a crucial role in the breakdown of sulfide, a compound that reaches toxic levels in individuals with ethylmalonic encephalopathy. Genetic analysis revealed ETHE1 mutations in all typical ethylmalonic encephalopathy patients. However, no ETHE1 mutations were found in patients exhibiting early-onset progressive encephalopathy accompanied by ethylmalonic aciduria.
Description
ETHE1 Human Recombinant, a single, non-glycosylated polypeptide chain, is produced in E.coli. It comprises 267 amino acids (13-254) and has a molecular weight of 29.1kDa. A 25 amino acid His-tag is fused to the N-terminus of ETHE1, and it undergoes purification using proprietary chromatographic techniques.
Physical Appearance
A clear, colorless solution that has been sterilized by filtration.
Formulation
The ETHE1 solution is prepared at a concentration of 1mg/ml and contains 20mM Tris-HCl buffer (pH 8.0), 100mM NaCl, and 10% glycerol.
Stability
For optimal storage, refrigerate the ETHE1 solution at 4°C if the entire vial will be used within 2-4 weeks. For extended storage, freeze the solution at -20°C. Adding a carrier protein (0.1% HSA or BSA) is advised for long-term storage. Repeated freezing and thawing of the solution should be avoided.
Purity
SDS-PAGE analysis indicates a purity greater than 90%.
Synonyms
Ethylmalonic encephalopathy protein 1, HSCO, Hepatoma subtracted clone one protein, YF13H12, protein ETHE1 mitochondrial, D83198, EC 3.1.2.6.
Source
E.coli.
Amino Acid Sequence
MGSSHHHHHH SSGLVPRGSH MGSHMLSQRG GSGAPILLRQ MFEPVSCTFT YLLGDRESRE AVLIDPVLET APRDAQLIKE LGLRLLYAVN THCHADHITG SGLLRSLLPG CQSVISRLSG AQADLHIEDG DSIRFGRFAL ETRASPGHTP GCVTFVLNDH SMAFTGDALL IRGCGRTDFQ QGCAKTLYHS VHEKIFTLPG DCLIYPAHDY HGFTVSTVEE ERTLNPRLTL SCEEFVKIMG NLNLPKPQQI DFAVPANMRC GVQTPTA

Product Science Overview

Introduction

Ethylmalonic Encephalopathy (EE) is a rare, inherited metabolic disorder that primarily affects the nervous system, blood vessels, and other body systems. It is caused by mutations in the ETHE1 gene, which encodes the enzyme ethylmalonic encephalopathy 1 (ETHE1). This enzyme plays a crucial role in the detoxification of hydrogen sulfide (H₂S) in the mitochondrial matrix .

Genetic Basis

The ETHE1 gene is located on chromosome 19q13 and encodes a sulphur dioxygenase enzyme. Mutations in this gene disrupt the normal function of the enzyme, leading to the accumulation of toxic metabolites, including ethylmalonic acid (EMA) and C4 acylcarnitine . These toxic substances cause damage to various tissues, particularly the brain, leading to the clinical manifestations of EE.

Clinical Manifestations

Ethylmalonic Encephalopathy presents with a range of symptoms that typically appear at birth or in early infancy. These symptoms include:

  • Neurological Symptoms: Developmental delay, hypotonia (weak muscle tone), seizures, and abnormal movements .
  • Vascular Symptoms: Petechiae (tiny red spots under the skin) and acrocyanosis (blue discoloration of the hands and feet due to reduced blood flow) .
  • Gastrointestinal Symptoms: Chronic bloody diarrhea and difficulty swallowing, leading to poor growth .
Diagnosis

Diagnosis of EE is based on clinical examination, laboratory testing of blood and urine, and imaging studies of the brain. Genetic testing can confirm the diagnosis by identifying mutations in the ETHE1 gene . Measurement of EMA and C4 acylcarnitine levels during metabolic attacks is critical for diagnosing EE .

Treatment

There is currently no cure for EE, but treatment focuses on managing symptoms and reducing the accumulation of toxic metabolites. Long-term treatment strategies include:

  • Medications: Metronidazole and N-acetylcysteine (NAC) to reduce sulfide accumulation .
  • Dietary Modifications: Specific dietary changes to manage symptoms.
  • Liver Transplantation: In some cases, liver transplantation may be considered.
  • Continuous Renal Replacement Therapy (CRRT): To help detoxify the body .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.